{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:53:04Z","timestamp":1791165184655,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":4146,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.ymthe.2005.01.012","type":"journal-article","created":{"date-parts":[[2005,3,13]],"date-time":"2005-03-13T01:14:13Z","timestamp":1110676453000},"page":"889-898","source":"Crossref","is-referenced-by-count":96,"title":["Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter"],"prefix":"10.1016","volume":"11","author":[{"given":"Baodong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talmage","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayn","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2005.01.012_bib1","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/104303401300042447","article-title":"Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease","volume":"12","author":"Pauly","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/104303401750195917","article-title":"Long-term efficacy after [E1\u2212, polymerase\u2212] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice","volume":"12","author":"Ding","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2005.01.012_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.gt.3300609","article-title":"Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle","volume":"5","author":"Pauly","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1525-0016(03)00022-4","article-title":"Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1525-0016(02)00055-2","article-title":"Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2005.01.012_bib10","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib11","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","article-title":"Gene therapy vectors based on adeno-associated virus type 1","volume":"73","author":"Xiao","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2005.01.012_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/JVI.72.1.309-319.1998","article-title":"Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 1","volume":"72","author":"Rutledge","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2005.01.012_bib13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2005.01.012_bib14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.gt.3301259","article-title":"Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"7","author":"Ferrer","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/104303401750061267","article-title":"Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies","volume":"12","author":"Cordier","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/mthe.2000.0089","article-title":"Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors","volume":"2","author":"Hauser","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib17","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/MCB.16.9.5058","article-title":"E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice","volume":"16","author":"Shield","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2005.01.012_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/sj.gt.3301829","article-title":"Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product","volume":"9","author":"Yuasa","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mthe.2002.0563","article-title":"Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction","volume":"5","author":"Ding","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib20","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","article-title":"Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy","volume":"10","author":"Raben","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2005.01.012_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1089\/10430349950016942","article-title":"Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy","volume":"10","author":"Loeb","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib23","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1073\/pnas.96.7.3906","article-title":"Sustained correction of bleeding disorder in hemophilia B mice by gene therapy","volume":"96","author":"Wang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib24","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2005.01.012_bib25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2005.01.012_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.gt.3300548","article-title":"Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia","volume":"5","author":"Monahan","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/mthe.2001.0441","article-title":"Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9","volume":"4","author":"Fields","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/mthe.2001.0442","article-title":"Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation","volume":"4","author":"Herzog","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib31","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1128\/JVI.75.14.6615-6624.2001","article-title":"Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors","volume":"75","author":"Halbert","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2005.01.012_bib32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1521-2254(200011\/12)2:6<444::AID-JGM132>3.0.CO;2-1","article-title":"Scalable chromatographic purification process for recombinant adeno-associated virus (rAAV)","volume":"2","author":"O\u2019Riordan","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2005.01.012_bib33","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/104303402320139014","article-title":"Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography","volume":"13","author":"Kaludov","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib34","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1089\/104303400750001390","article-title":"Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo","volume":"11","author":"Gao","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2144\/03341dd07","article-title":"Optimized production of high-titer recombinant adeno-associated virus in roller bottles","volume":"34","author":"Liu","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2005.01.012_bib36","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1089\/10430349950016861","article-title":"High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H","volume":"10","author":"Zhang","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib37","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1089\/10430340260355347","article-title":"Insect cells as a factory to produce adeno-associated virus type 2 vectors","volume":"13","author":"Urabe","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.gt.3300378","article-title":"Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy","volume":"4","author":"Amalfitano","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib40","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S1525-0016(16)41454-1","article-title":"Development of a new, immune-deficient, GSD-II mouse model confirms that anti-GAA antibody can limit the efficacy of gene therapy for GSD-II","volume":"7","author":"Fang","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.01.012_bib41","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2005.01.012_bib42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/geno.1997.4919","article-title":"The murine DNA-PKcs gene consists of 86 exons dispersed in more then 250 kb","volume":"45","author":"Fujimori","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.ymthe.2005.01.012_bib43","doi-asserted-by":"crossref","first-page":"10285","DOI":"10.1073\/pnas.93.19.10285","article-title":"Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse","volume":"93","author":"Blunt","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib44","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1073\/pnas.94.6.2438","article-title":"Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice","volume":"94","author":"Araki","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2005.01.012_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.01.012_bib47","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T09:09:53Z","timestamp":1586164193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001605000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1525001605000225"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2005.01.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}